Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Pramlintide

TOTT

AstraZeneca · Phase 2/3 · Withdrawn · Enrollment 0

NCT06619015

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutide and placebon/rn/rn/rn/r
Semaglutide and pramlintiden/rn/rn/rn/r

Not shown

  • Semaglutide and placebo: endpoint not reported
  • Semaglutide and pramlintide: endpoint not reported